Home » Stocks » GBS

GBS, Inc. (GBS)

Stock Price: $6.08 USD -0.22 (-3.49%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $7.00 +0.92 (15.13%) Mar 5, 7:51 PM
Market Cap 72.20M
Revenue (ttm) 405,931
Net Income (ttm) n/a
Shares Out 8.62M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $6.08
Previous Close $6.30
Change ($) -0.22
Change (%) -3.49%
Day's Open 6.35
Day's Range 5.80 - 6.51
Day's Volume 150,349
52-Week Range 5.71 - 14.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their pr...

GlobeNewsWire - 2 months ago

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and t...

Barrons - 2 months ago

GBS and Inhibikase Therapeutics priced late Tuesday.

Other stocks mentioned: IKT
GlobeNewsWire - 2 months ago

Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”

GlobeNewswire - 2 months ago

Will Trade on the Nasdaq Global Market Under Ticker “GBS”

NASDAQ - 2 months ago

GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now ...

About GBS

GBS operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a... [Read more...]

Industry
Medical Devices
IPO Date
Dec 23, 2020
CEO
Harry Simeonidis
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
GBS
Full Company Profile

Financial Performance

In 2020, GBS, Inc.'s revenue was $188,841, an increase of 100,347.34% compared to the previous year's $188. Losses were -$3.13 million, -57.27% less than in 2019.

Financial Statements